Embryo Expands Its Agency Portfolio with Acquisition of Manchester's Serotonin

Embryo, a prominent independent digital marketing agency based in the UK, has announced the acquisition of Manchester-based creative and digital agency Serotonin. This strategic move, completed on March 9, 2026, marks a significant step in Embryo's ongoing expansion efforts, adding scale and specialist capabilities to its service offerings.

Founded in 2019 by Dom Carter and Clair Heaviside, Serotonin has grown from its Northern Quarter base to serve clients on a global scale. The agency has established a strong reputation for combining strategic thinking with creative execution, developing campaigns that propel brands forward. This reputation aligns well with Embryo's ambition to integrate innovative strategies and enhance its overall marketing solutions.

The acquisition of Serotonin follows Embryo's previous purchases of Making You Content in April 2025 and Novaro in November 2025. Embryo's leadership indicated that the integration of Serotonin’s expertise will enhance their capabilities in brand development, performance marketing, and creative solutions. This move promises to provide clients with a comprehensive suite of services – from positioning and storytelling to digital performance and technology growth.

As part of the acquisition transition, Clair Heaviside will step into the role of Chief Creative Officer at Embryo, while Dom Carter will serve as Chief Strategy Officer. In their new positions, they will be responsible for bolstering Embryo’s creative offerings and shaping the agency's strategic direction. Carter emphasised the importance of combining strong strategy with standout creativity, stating, "We’ve always believed that great marketing sits at the intersection of strong strategy and standout creativity. Embryo has built an impressive reputation for performance and growth, and the opportunity to bring Serotonin’s brand and creative capability into that environment felt like a natural next step."

Ross Green, one of Embryo's founders, also expressed enthusiasm about the acquisition, emphasising Serotonin’s track record of impactful creative work. He stated, "Bringing their team into Embryo strengthens what we can offer our clients and accelerates our vision of building a truly integrated agency. Dom and Clair bring enormous strategic and creative expertise, and we’re excited about what we can build together."

With this acquisition, the leadership teams from both Embryo and Serotonin will collaborate to integrate operations effectively and expand the overall capabilities of the agency. This move underscores Embryo's commitment to enhancing its market presence and solidifies its objective of becoming one of the UK's most respected independent marketing agencies.

The acquisition of Serotonin represents a broader trend in the agency sector towards consolidation and integration, as agencies seek to bolster their propositions and offer comprehensive, end-to-end solutions in an increasingly competitive landscape. As Embryo continues to explore additional growth opportunities, the potential for further expansion remains significant.

Source: Prolific North